114798-26-4
114798-26-4
Chemical Structure
Losartan
Synonym(s): DuP-753
- CAS No.: 114798-26-4
- Formula:C22H23ClN6O
- Molecular Weight:422.91
IUPAC Name: (1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol
InChIKey: PSIFNNKUMBGKDQ-UHFFFAOYSA-N
SMILES: OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2
Biological Activity: Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Losartan | 99.41% | Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Losartan (Standard) | ≥98% | Losartan (Standard) is the analytical standard of Losartan. This product is intended for research and analytical applications. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Losartan-d2 | Losartan-d2 is the deuterium labeled Losartan. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Losartan-d9 | Losartan-d9 is the deuterium labeled Losartan. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Losartan-d4 | 99.42% | Losartan-d4 is the deuterium labeled Losartan. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
